To further assess the prognostic relevance of TIES in immunotherapy, we analyzed its performance in the GSE183924 dataset, which includes 37 gastric cancer patients who underwent postoperative durvalumab (anti‐PD‐L1) therapy [22] Patients were classified into high‐ and low‐TIES groups based on the median TIES. The gene discussed is CD274; the disease is gastric cancer.